HIGHLIGHTS
- who: Taylor Feehley from the (UNIVERSITY) have published the research work: Drugging the epigenome in the age of precision medicine, in the Journal: (JOURNAL)
- how: Subsequent studies were conducted in myelodysplastic syndrome (MDS) using lower doses leading to FDA approvals for Bristol Myers Squibb .
- future: With more recent advances however the authors believe epigenetic therapies are poised to become an important component of patient care in the near future . And future directions While the evolution of the epigenetic therapeutics field has been marked by modest success alongside notable disappointments the rise of new . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.